Pharmacokinetic principles of immunosuppressive drugs

Annals of Transplantation

Volumn 13, Issue 3, 2008, Pages 5-10

  Budde, Klemens ^a   Glander, Petra ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Inter patient variability; Pharmacodynamic monitoring; Pharmacokinetic parameter; Therapeutic window

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN; CYTOCHROME P450; EVEROLIMUS; GLYCOPROTEIN P; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID; RAPAMYCIN; TACROLIMUS;

ACUTE GRAFT REJECTION; AGE DISTRIBUTION; ANTIBODY INDUCTION THERAPY; AREA UNDER THE CURVE; ARTICLE; CHRONIC KIDNEY FAILURE; CIRCADIAN RHYTHM; CYTOKINE RELEASE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; DRUG MONITORING; DRUG TARGETING; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC POLYMORPHISM; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; LYMPHOCYTE PROLIFERATION; NEPHROTOXICITY; POLYMERASE CHAIN REACTION; RENAL REPLACEMENT THERAPY; TH1 CELL; TH2 CELL; CELLULAR IMMUNITY; METHODOLOGY; REVIEW;

DRUG MONITORING; HUMANS; IMMUNITY, CELLULAR; IMMUNOSUPPRESSIVE AGENTS;

EID: 58749102772     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Halloran PF: Immunosuppressive drugs for kidney transplantation. N Engl J Med, 2004; 351: 2715-29
2. Nankivell BJ, Borrows RJ, Fung CL et al: The natural history of chronic allograft nephropathy. N Engl J Med, 2003; 349: 2326-33
3. Ojo AO, Held PJ, Port FK et al: Chronic renal failure after transplantation of a nonrenal organ N Engl J Med, 2003; 349: 931-40
4. Frimat L, Cassuto-Viguier E, Charpentier B et al: Impact of cyclosporine reduction with MMF: a randomized trial in chronic allograft dysfunction. The 'reference' study. Am J Transplant, 2006; 6: 2725-34
5. Dantal J, Hourmant M, Cantarovich D et al: Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet, 1998; 351: 623-28
6. Budde K, Bosmans JL, Sennesael J et al: Reducedexposure cyclosporine is safe and effi cacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab. Clin Nephrol, 2007; 67: 164-75
7. Kahan B: Sirolimus: a comprehensive review. Expert Opin Pharmacother, 2001; 2: 1903-17
8. Knight RJ, Kahan BD: The place of sirolimus in kidney transplantation: can we reduce calcineurin inhibitor renal toxicity? Kidney Int, 2006; 70: 994-99
9. Ekberg H, Tedesco-Silva H, Demirbas A et al: ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med, 2007; 357: 2562-75
10. Ekberg H, Grinyó J, Nashan B et al: Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant, 2007; 7: 560-70
11. Nashan B, Bock A, Bosmans JL et al: Use of Neoral C monitoring: a European consensus. Transpl Int, 2005; 18: 768-78
12. van Hest RM, van Gelder T, Bouw R et al: Time-dependent clearance of mycophenolic acid in renal transplant recipients. Br J Clin Pharmacol, 2007; 63: 741-52
13. Einecke G, Schütz M, Mai I et al: Limitations of C2 monitoring in renal transplant recipients. Nephrol Dial Transplant, 2005; 20: 1463-70
14. Hale MD, Nicholls AJ, Bullingham RE et al: The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther, 1998; 64: 672-83
15. van Hest R, Mathot R, Vulto A et al: Predicting the usefulness of therapeutic drug monitoring of mycophenolic acid: a computer simulation. Ther Drug Monit, 2005; 27: 163-67
16. Curtis JJ, Jones P, Barbeito R: Large within-day variation in cyclosporine absorption: circadian variation or food effect? Clin J Am Soc Nephrol, 2006; 1: 462-66
17. Lemeur Y, Büchler M, Thierry A et al: Individualized mycophenolate mofetil dosing based on drug exposure signifi cantly improves patient outcomes after renal transplantation. Am J Transplant, 2007; 7: 2496-503
18. van Gelder T, Tedesco-Silva H, de Fijter H et al: An open, prospective, randomised, controlled, multi-centre study comparing Fixed Dose vs Concentration Controlled mycophenolate mofetil regimens for de novo patients following renal transplantation (the FDCC trial). Transplantation, 2008 (in press)
19. Arns W, Cibrik DM, Walker RG et al: Therapeutic drug monitoring of mycophenolic acid in solid organ transplant patients treated with mycophenolate mofetil: review of the literature. Transplantation, 2006; 82: 1004-12
20. Oellerich M, Barten MJ, Armstrong VW: Biomarkers: the link between therapeutic drug monitoring and pharmacodynamics. Ther Drug Monit, 2006; 28: 35-38
21. Dambrin C, Klupp J, Morris RE: Pharmacodynamics of immunosuppressive drugs. Curr Opin Immunol, 2000; 12: 557-62
22. Ransom JT: Mechanism of action of mycophenolate mofetil. Ther Drug Monit, 1995; 17: 681-84
23. Budde K, Glander P, Bauer S et al: Pharmacodynamic monitoring of mycophenolate mofetil. Clin Chem Lab Med, 2000; 38: 1213-16
24. Glander P, Hambach P, Braun KP et al: Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am J Transplant, 2004; 4: 2045-51
25. Halloran PF, Helms LM, Kung L, Noujaim J: The temporal profi le of calcineurin inhibition by cyclosporine in vivo. Transplantation, 1999; 68: 1356-61
26. Batiuk TD, Pazderka F, Enns J et al: Cyclosporine inhibition of calcineurin activity in human leukocytes in vivo is rapidly reversible. J Clin Invest, 1995; 96: 1254-60
27. Rostaing L, Puyoo O, Tkaczuk J et al: Differences in Type 1 and Type 2 intracytoplasmic cytokines, detected by fl ow cytometry, according to immunosuppression (cyclosporine A vs. tacrolimus) in stable renal allograft recipients. Clin Transplant, 1999; 13: 400-9
28. Rostaing L, Tkaczuk J, Durand M et al: Kinetics of intracytoplasmic Th1 and Th2 cytokine production assessed by fl ow cytometry following in vitro activation of peripheral blood mononuclear cells. Cytometry, 1999; 35: 318-28
29. Strehlau J, Pavlakis M, Lipman M et al: Quantitative detection of immune activation transcripts as a diagnostic tool in kidney transplantation. Proc Natl Acad Sci USA, 1997; 94: 695-700
30. Budde K, Waiser J, Ceska M et al: Interleukin-8 expression in patients after renal transplantation. Am J Kidney Dis, 1997; 29: 871-80
31. Waiser J, Budde K, Katalinic A et al: Interleukin-6 expression after renal transplantation. Nephrol Dial Transplant, 1997; 12: 753-59
32. Waiser J, Schneider M, Eljazyfer S et al: Profibrotic cytokines and lymphocyte proliferation in stable renal allograft recipients treated with or without cyclosporine A. Clin Immunol, 2006; 119: 59-66
33. Wu J, Palladino MA, Figari IS, Morris RE: Comparative immunoregulatory effects of rapamycin, FK 506 and cyclosporine on mitogen-induced cytokine production and lymphoproliferation. Transplant Proc, 1991; 23: 238-40
34. Giese T, Zeier M, Meuer S: Analysis of NFAT-regulated gene expression in vivo: a novel perspective for optimal individualized doses of calcineurin inhibitors. Nephrol Dial Transplant, 2004; 19(Suppl.4): 55-60
35. Gummert JF, Barten MJ, Sherwood SW et al: Pharmacodynamics of immunosuppression by mycophenolic acid: inhibition of both lymphocyte proliferation and activation correlates with pharmacokinetics. J Pharmacol Exp Ther, 1999; 291: 1100-12
36. Barten MJ, Gummert JF, van Gelder T et al: Flow cytometric quantitation of calcium-dependent and-independent mitogen-stimulation of T cell functions in whole blood: inhibition by immunosuppressive drugs in vitro. J Immunol Methods, 2001; 253: 95-112
37. Stalder M, Bîrsan T, Holm B et al: Quantification of immunosuppression by flow cytometry in stable renal transplant recipients. Ther Drug Monit, 2003; 25: 22-27
38. Israeli M, Yussim A, Mor E et al: Preceeding the rejection: in search for a comprehensive posttransplant immune monitoring platform. Transpl Immunol, 2007; 18: 7-12
39. Burkhart C, Heusser C, Morris RE et al: Pharmacodynamics in the development of new immunosuppressive drugs. Ther Drug Monit, 2004; 26: 588-92